Straits Times Index
3,410.81 -29.07 (-0.85%) Nikkei
40,912.37 -1.28 (-0.00%) Hang Seng
17,799.61 -228.67 (-1.27%) FTSE 100
8,203.93 -37.33 (-0.45%) Bitcoin USD
56,797.63 -8.40 (-0.01%) CMC Crypto 200
1,179.87 -28.83 (-2.39%)
BTAI Jan 2025 1.500 call
- GlobeNewswire
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatment Results supportive of Phase 3 SERENITY and TRANQUILITY programs NEW HAVEN, Conn., June 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial int
- GlobeNewswire
BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jefferies Global Healthcare Conference in New York City. The presentation is set for Wednesday, June 5 at 3 p.m. ET, and will highlight BioXcel Therapeutics’ late-stage clinical programs with BXCL501 for th
- GlobeNewswire
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
NEW HAVEN, Conn., May 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that Rob Risinger, M.D., Chief Medical Officer of Neuroscience, will deliver oral and poster presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. The meeting will take place May 28 to 31, 2024 in Miami Beach, FL
